loading
전일 마감가:
$24.67
열려 있는:
$25.93
하루 거래량:
7.35M
Relative Volume:
1.98
시가총액:
$17.43B
수익:
$956.00K
순이익/손실:
$-221.32M
주가수익비율:
-87.19
EPS:
-0.32
순현금흐름:
$-142.25M
1주 성능:
+18.90%
1개월 성능:
+36.36%
6개월 성능:
+46.92%
1년 성능:
+587.19%
1일 변동 폭
Value
$25.81
$29.99
1주일 범위
Value
$22.84
$29.99
52주 변동 폭
Value
$2.10
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
명칭
Summit Therapeutics Inc
Name
전화
305-203-2034
Name
주소
601 BRICKELL KEY DRIVE, MIAMI
Name
직원
159
Name
트위터
@summitplc
Name
다음 수익 날짜
2025-02-24
Name
최신 SEC 제출 서류
Name
SMMT's Discussions on Twitter

SMMT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SMMT
Summit Therapeutics Inc
27.90 17.43B 956.00K -221.32M -142.25M -0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-26 업그레이드 Citigroup Neutral → Buy
2025-03-21 개시 Cantor Fitzgerald Overweight
2025-03-12 개시 Evercore ISI Outperform
2025-02-28 개시 Goldman Buy
2025-01-08 개시 Truist Buy
2024-12-11 개시 Wells Fargo Overweight
2024-12-06 개시 Jefferies Buy
2024-11-04 개시 JMP Securities Mkt Outperform
2024-09-27 다운그레이드 Citigroup Buy → Neutral
2024-08-12 개시 H.C. Wainwright Buy
2024-05-07 개시 Citigroup Buy
2024-03-26 개시 Stifel Buy
2018-06-28 다운그레이드 Janney Buy → Neutral
2018-05-02 개시 Janney Buy
2018-04-12 재확인 Needham Buy
2018-02-13 개시 BTIG Research Buy
2018-01-04 개시 SunTrust Buy
2017-12-01 재개 H.C. Wainwright Buy
2016-11-16 재확인 RBC Capital Mkts Outperform
2016-10-05 재확인 Needham Buy
2016-09-16 개시 H.C. Wainwright Buy
2015-03-30 개시 Needham Buy
2015-03-30 개시 Oppenheimer Outperform
모두보기

Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스

pulisher
May 02, 2025

Summit Therapeutics (SMMT) Stock: Goldman Sachs Raises Price Target | SMMT Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating - TipRanks

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - Zacks Investment Research

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 02, 2025
pulisher
May 02, 2025

This Soaring Stock Just Delivered More Good News. Time to Buy? - The Globe and Mail

May 02, 2025
pulisher
May 02, 2025

Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics (SMMT) Advances with Ivonescimab in Key Tria - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025
pulisher
May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics (SMMT) Beats Q1 Earnings Expectations - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Inc Reports Q1 2025 EPS of $(0.09), Aligning with Estimates; Revenue Unreported - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics (SMMT) Sees Balanced Options Activity Ahead - GuruFocus

May 01, 2025
pulisher
Apr 30, 2025

Summit Therapeutics (SMMT) Earnings Report Expected Amidst Mixed Forecasts - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Summit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past Month - Yahoo Finance

Apr 30, 2025
pulisher
Apr 28, 2025

Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics, Intel among Monday’s market cap stock movers By Investing.com - Investing.com South Africa

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics, Intel among Monday’s market cap stock movers - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $44 target despite drop - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $44 target despite drop By Investing.com - Investing.com India

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $40 target at Citizens JMP By Investing.com - Investing.com Canada

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $40 target at Citizens JMP - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics Shares Tumble Amid Trial Data Concerns - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market O - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? - MSN

Apr 28, 2025
pulisher
Apr 27, 2025

Summit Therapeutics (SMMT) Shares Plummet After Survival Data Di - GuruFocus

Apr 27, 2025
pulisher
Apr 26, 2025

Akeso survival data for ivonescimab misses expectations, STAT says - Yahoo Finance

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT) - Seeking Alpha

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics Stock Plummets Amid Study Setback - Evrim Ağacı

Apr 26, 2025
pulisher
Apr 26, 2025

BioNTech And Summit Therapeutics Stocks Fluctuate Dramatically - Evrim Ağacı

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics (SMMT) Reports Ivonescimab's Approval in Chi - GuruFocus

Apr 26, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Observes Notable Progress with Ivones - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics, Saia, And T-Mobile US Take A Hit In Trading - Finimize

Apr 25, 2025
pulisher
Apr 25, 2025

Akeso (AKESF) and Summit Therapeutics (SMMT) See Stock Declines After Drug Data Release | BNTX Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Merck (MRK) Reacts to Summit Therapeutics' Lung Cancer Therapy D - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Market Today: Alphabet's Earnings Boost Tech, Summit Therapeutics Plummets - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - Mitrade

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Price Target Raised Amid Positive Dru - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Sees Stock Drop Despite Positive Drug - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics Gets Approval From China's Health Authority for Second Use of Ivonescimab - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial - Fierce Pharma

Apr 25, 2025
pulisher
Apr 25, 2025

Citi says buy Summit amid ‘significant market confusion’ - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Merck gains after latest survival data for Summit’s cancer drug - MSN

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Shares Resume Trading After Drug Appr - GuruFocus

Apr 25, 2025

Summit Therapeutics Inc (SMMT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$32.89
price up icon 1.26%
$21.48
price up icon 2.63%
$72.30
price down icon 0.47%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
자본화:     |  볼륨(24시간):